- Home
- GNLX vs ANVS Comparison
GNLX vs ANVS Comparison
Compare GNLX & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- ANVS
- Stock Information
- Founded
- GNLX 2001
- ANVS 2008
- Country
- GNLX United States
- ANVS United States
- Employees
- GNLX N/A
- ANVS N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- GNLX Health Care
- ANVS Health Care
- Exchange
- GNLX Nasdaq
- ANVS Nasdaq
- Market Cap
- GNLX 184.4M
- ANVS 31.2M
- IPO Year
- GNLX 2023
- ANVS 2020
- Fundamental
- Price
- GNLX $3.64
- ANVS $1.66
- Analyst Decision
- GNLX Strong Buy
- ANVS Strong Buy
- Analyst Count
- GNLX 4
- ANVS 5
- Target Price
- GNLX $18.25
- ANVS $37.00
- AVG Volume (30 Days)
- GNLX 201.9K
- ANVS 447.8K
- Earning Date
- GNLX 03-31-2025
- ANVS 03-31-2025
- Dividend Yield
- GNLX N/A
- ANVS N/A
- EPS Growth
- GNLX N/A
- ANVS N/A
- EPS
- GNLX N/A
- ANVS N/A
- Revenue
- GNLX $8,000.00
- ANVS N/A
- Revenue This Year
- GNLX N/A
- ANVS N/A
- Revenue Next Year
- GNLX N/A
- ANVS N/A
- P/E Ratio
- GNLX N/A
- ANVS N/A
- Revenue Growth
- GNLX N/A
- ANVS N/A
- 52 Week Low
- GNLX $1.60
- ANVS $1.53
- 52 Week High
- GNLX $7.04
- ANVS $20.00
- Technical
- Relative Strength Index (RSI)
- GNLX 45.34
- ANVS 19.82
- Support Level
- GNLX $3.51
- ANVS $1.57
- Resistance Level
- GNLX $4.37
- ANVS $1.77
- Average True Range (ATR)
- GNLX 0.45
- ANVS 0.18
- MACD
- GNLX -0.13
- ANVS 0.07
- Stochastic Oscillator
- GNLX 22.95
- ANVS 8.38
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.